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Frontiers of valvular heart disease: from
aortic stenosis to the tricuspid valve and
congenital anomalies
Thomas F. Lu¨scher, MD, FESC
Editor-in-Chief, Zurich Heart House, Careum Campus, Moussonstrasse 4, 8091 Zurich, Switzerland
Valvular heart disease has moved from being the Cinderella of cardi-
ology to centre stage in recent years. The development of
transcatheter aortic valve implantation or TAVI1 and its remarkable
clinical sucess2 have stimulated epidemiological3 and outcomes re-
search, imaging as a modality for the planning of such interventions,4,5
technological research for new and better tools for such proced-
ures,6,7 and more recently also the field of antiplatelet agents and
antithrombotics. The most recent progress is summarized in a
Current Opinion ‘The year in cardiology 2016: valvular heart
disease’, by Ottavio Alfieri and colleagues from the San Raffaele
University Hospital in Milan, Italy.8 The authors note that as expected
in this era of rapidly evolving therapeutic modalities and technologies,
many scientific contributions are related to the expanded role of per-
cutaneous interventions. New data are now available, consolidating
the validity of the transcatheter approach in a variety of subsets of pa-
tients and therefore offering new strategies and perspectives in man-
agement as outlined in detail in their comprehensive review.
A novel frontier in valvular heart disease is the tricuspid valve, as
reviewed by Paul A. Grayburn and colleagues from the Baylor Heart
and Vascular Institute in Dallas, Texas in their article ‘Tricuspid re-
gurgitation: diagnosis and treatment’.9 The authors note that
tricuspid regurgitation is the most common lesion of the tricuspid
valve, with mild regurgitation being common and usually benign.
However, moderate or severe tricuspid regurgitation can lead to ir-
reversible myocardial damage and adverse outcomes. Despite these
findings, few patients with significant tricuspid regurgitation undergo
surgery. Indeed, the treatment of functional or secondary tricuspid
regurgitation remains controversial because of high rates of residual
or recurrent tricuspid regurgitation and poor outcomes following
surgery. Traditional teaching that functional tricuspid regurgitation
resolves on its own if the underlying disease is successfully treated
has proven to be incorrect. This review therefore aims to clarify the
current management of tricuspid regurgitation by describing the anat-
omy, pathophysiology, diagnosis, and treatment of tricuspid regurgi-
tation, including the eventual possibility of percutaneous tricuspid
valve therapy.
The latter, most innovative aspect is discussed in detail in a second
clinical review manuscript entitled ‘Percutaneous tricuspid valve
therapies: the new frontier’ by Maurizio Taramasso and col-
leagues from the University Hospital, Zurich, Switzerland.10 The au-
thors remind us that moderate to severe tricuspid regurgitation
affects1.6 million patients in the USA, of whom only 8000 undergo
tricuspid surgery annually, leaving an extremely large number of pa-
tients untreated. Percutaneous procedures are an attractive alterna-
tive to surgery for patients deemed to be high-risk surgical
candidates. Whereas over the past few years, the development and
clinical use of percutaneous approaches such as TAVI, Mitraclip, and
mitral valve replacement has increased dramatically, only little pro-
gress has been made as regards to the percutaneous treatment of
tricuspid regurgitation. In this review, the currently available technol-
ogies, among them Mitraclip11,12 and novel devices,13,14 which are
currently under evaluation, mostly echo-guided,15 are described in
detail and their preliminary clinical results discussed.
As with TAVI, any other percutaneous valve intervention requires
careful planning using state-of-the-art imaging modalities, in particular
computed tomography (CT). In their clinical research article
‘Computed tomography for planning transcatheter tricus-
pid valve therapy’, Jeroen J. Bax and colleagues from the Leiden
University Medical Center in The Netherlands16 propose a compre-
hensive anatomical evaluation of the tricuspid valve, right ventricle,
and vena cavae, and its spatial relationship with the right coronary ar-
tery using CT and investigates the implications for suitability for cur-
rent technologies as described in the above discussed review by
Taramasso et al. To evaluate this approach, a total of 250 patients
undergoing CT were divided according to the presence of moderate
or severe tricuspid regurgitation and less than moderate tricuspid re-
gurgitation. Tricuspid valve annulus, right ventricle, and vena cavae di-
mensions and the course of the right coronary artery relative to the
tricuspid annulus were evaluated. Patients with severe tricuspid re-
gurgitation showed significantly larger dimensions of the tricuspid an-
nulus, right ventricle, and vena cavae. In two-thirds of the patients,
the right coronary artery coursed along the tricuspid valve annulus
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..(Figure 1). Patients with less severe tricuspid regurgitation more fre-
quently showed a course of the right coronary artery superior to the
tricuspid annulus at the levels of the anterior and the posterior tricus-
pid leaflet compared with their counterparts. A less favourable
course of the right coronary artery at <_ 2.0 mm distance from the an-
nulus for current annuloplasty techniques was observed at the level
of the anterior tricuspid and posterior leaflets in 13% and 28%, re-
spectively, of patients with severe tricuspid regurgitation. Thus, this is
the first systematic approach using CT to define suitability of patients
for current transcatheter tricuspid valve devices.
While the most common forms of valvular heart disease affect
mainly elderly patients with calcific aortic stenosis as outlined above
or functional mitral regurgitation due to heart failure15,17 or other
conditions, congenital anomalies of arterial valves are overall rare,
but are common birth defects leading mainly to valvular stenosis.
With no pharmaceutical treatment that can prevent disease progres-
sion, prosthetic replacement is currently the only treatment choice,
incurring considerable morbidity and mortality. Animal models pre-
senting localized anomalies and stenosis of congenital arterial valves
like those of humans are important research tools to uncover
developmental molecular mechanisms underlying this condition. In a
Basic Science article ‘Notch–Tnf signalling is required for de-
velopment and homeostasis of arterial valves’, Bin Zhou and
colleagues from the Yeshiva University Albert Einstein College of
Medicine in Bronx, New York generated and characterized mouse
models with conditionally altered Notch signalling in endothelial or
interstitial cells of developing valves.18 Mice with inactivation of
Notch1 signalling in valvular endothelial cells developed congenital
anomalies of arterial valves including bicuspid aortic valves and valvu-
lar stenosis. Notch1 signalling in valvular endothelial cells was
required for repressing proliferation and activating apoptosis of
valvular interstitial cells after endocardial to mesenchymal transform-
ation (Figure 1). Indeed, the authors showed that Notch signalling
regulated tumour necrosis factor a (TNFa) expression in vivo, and
TNF signalling was necessary for apoptosis of valvular interstitial cells
and post-endocardial to mesenchymal transformation development
of arterial valves. Further, activation or inhibition of Notch signalling
in cultured pig aortic valvular endothelial cells promoted or sup-
pressed apoptosis of valvular interstitial cells, respectively. Thus, the
authors conclude that they here for the first time provide animal
Figure 1 Assessment of the distance between the right coronary artery (RCA) and the tricuspid valve annulus.The long-axis 2- and 4-chamber
views (A and B) were aligned to reconstruct a short-axis view of the tricuspid valve annulus (C). At the level of the anterior and posterior tricuspid
valve leaflet insertions, the distance to the RCA was assessed. Panel D shows the volume rendered reconstruction demonstrating the course of the
RCA completely along the tricuspid valve annulus. (from van Rosendael PJ, Kamperidis V, Kong WKF, van Rosendael AR, van der Kley F, Ajmone
Marsan N, Delgado V, Bax JJ. Computed tomography for planning transcatheter tricuspid valve therapy. See pages 665–674.)
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models and show that Notch–TNFa signalling balances proliferation
and apoptosis for post-endocardial to mesenchymal transformation
development of arterial valves. Their results suggest that mutations in
its components may lead to congenital anomaly of aortic valves and
valvar stenosis in humans. These provocative findings are further dis-
cussed in an interesting Editorial by Robert Henry Anderson from
Newcastle University in London, UK.19
Heart failure is an important complication of valvular, coronary, or
hypertensive heart disease. Although huge progress has been made
in this condition, as again outlined by the most recent ESC
Guidelines,20 treatment remains essentially palliative in nature. Thus,
novel regenerative approaches have been tested with some posi-
tive,21 but mainly neutral results.22,23 However, cardiopoietic cells,
produced through cardiogenic conditioning of patients’ mesenchymal
stem cells, have shown preliminary efficacy. In a FAST TRACK enti-
tled ‘Cardiopoietic cell therapy for advanced ischaemic
heart failure: results at 39 weeks of the prospective,
randomized, double-blind, sham-controlled CHART-1 clin-
ical trial’, Andre Terzic and colleagues for the CHART Program
present results of the Congestive Heart Failure Cardiopoietic
Figure 2 Notch1 in valvular endothelial cells promotes apoptosis of valvar interstitial cells during development of arterial valves. TUNEL assay
shows apoptotic cells (green) in arterial valves of E14.5 control (A and D), N1KO (B and E), and N1ICDþ embryos (C and F). Pecam1 staining marks
valvar endothelial cells (red). Bar = 50 lm. (G) and (H) show quantitative results. The data are presented as the ratio of TUNELþ cells/total valvar
endothelial cells or valvar interstitial cells. Statistical comparison was performed using one-way analysis of variance followed by Tukey’s test. A P-value
of, 0.05 was considered significant. Asterisk indicates comparison with the control in each individual valve leaflet, hash indicates comparison with the
non-adjacent leaflet (G) or anterior leaflet (H) in each genotype, and open triangle indicates comparison with the left coronary leaflet (G) in each
genotype. (from Wang Y, Wu B, Farrar E, Lui W, Lu P, Zhang D, Alfieri CM, Mao K, Chu M, Yang D, Xu D, Rauchman M, Taylor V, Conway
SJ, Yutzey KE, Butcher JT, Zhou B. Notch-Tnf signalling is required for development and homeostasis of arterial valves. See pages 675–686.)
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.Regenerative Therapy trial that aimed to validate cardiopoiesis-based
biotherapy in a larger heart failure cohort.24 This multinational,
randomized, double-blind, sham-controlled study was conducted in
39 hospitals. A total of 484 patients with symptomatic ischaemic
heart failure on guideline-directed therapy were screened and 348
underwent bone marrow harvest and mesenchymal stem cell expan-
sion. Of those, 315 who achieved >24 million mesenchymal stem
cells were randomized to cardiopoietic cells delivered endomyocar-
dially with a retention-enhanced catheter or sham procedure. Of the
271 patients, procedures were performed as randomized in 271. The
primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical
composite of all-cause mortality, worsening heart failure, Minnesota
Living with Heart Failure Questionnaire score, 6-min walk distance,
left ventricular end-systolic volume, and ejection fraction at 39 weeks.
The primary outcome was neutral. Exploratory analyses suggested a
benefit of cell treatment on the primary composite in the two-thirds
of the patients with baseline left ventricular end-diastolic volume
200–370 mL. No difference was observed in serious adverse events.
One cardiopoietic cell patient and nine sham patients experienced
aborted or sudden cardiac death. Thus, the authors conclude that
the primary endpoint was neutral, with safety demonstrated across
the cohort. Further evaluation of cardiopoietic cell therapy in patients
with elevated end-diastolic volume is warranted. These findings are
put into perspective in an Editorial authored by Joshua M. Hare
from the University of Miami in Florida, USA.25
The editors hope that this issue of the European Heart Journal will
be of interest to its readers.
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